STEVENSON, MD--(Marketwire - Nov 15, 2011) - Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the District of Maryland on behalf of purchasers of the common stock of Human Genome Sciences, Inc. ("HGSI" or the "Company") (NASDAQ: [ HGSI ]) during the period between July 20, 2009 and November 11, 2010, inclusive (the "Class Period"), including all persons who acquired the common stock of HGSI in the Company's July 28, 2009 public offering at $14 per share and in its December 2, 2009 public offering of common stock at $26.75.

If you have suffered a net loss for all transactions in Human Genome Sciences, Inc. common stock during the Class Period, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at [ www.browerpiven.com ], by email at [ hoffman@browerpiven.com ], by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years. Brower Piven has extensive experience litigating cases against pharmaceutical companies involving shareholder claims arising from and/or connected with the clinical trial and drug approval process.

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than January 10, 2012 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages or to serve as a Lead Plaintiff.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the Company's failure to disclose during the Class Period that its potential new drug, Benlysta, also called belimumab, for the treatment of Systemic Lupus Erythematosus (a chronic, life-threatening autoimmune disease) is associated with suicide. According to the complaint, after, on November 12, 2010, the U.S. Food and Drug Administration posted its analysis of Benlysta including the association between Benlysta and suicide in the clinical trials, the value of HGSI shares declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.